CXCL8 and cancer: Anti-IL-8 treatment has not been evaluated yet in HF patients, although an antibody targeting IL-8 (BMS-986253) is being tested in clinical trials involving patients with malignant tumors or patients with COVID-19 (Bilusic et al., 2019; Dallos, 2020).